ICG-001
ICG-001 Basic information
- Product Name:
- ICG-001
- Synonyms:
-
- (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide
- (6S,9aS)-6-(4-hydroxybenzyl)-N-benzyl-8-(naphthalen-1-ylmethyl)-4,7-dioxo-hexahydro-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide
- ICG-001;ICG001;(6S,9AS)-6-(4-HYDROXYBENZYL)-N-BENZYL-8-(NAPHTHALEN-1-YLMETHYL)-4,7-DIOXO-HEXAHYDRO-2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE
- 2H-PYRAZINO[1,2-A]PYRIMIDINE-1(6H)-CARBOXAMIDE,HEXAHYDRO-6-[(4-HYDROXYPHENYL)METHYL]-8-(1-NAPHTHALENYLMETHYL)-4,7-DIOXO-N-(PHENYLMETHYL)-,(6R,9AR)-REL-
- (6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylMethyl)-
- (6S,9AS)-6-(4-HYDROXYBENZYL)-8-NAPHTHALEN-1-YLMETHYL-4,7-DIOXO-HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-1-CARBOXYLIC ACID BENZYLAMIDE
- (6S,9aS)-rel-Hexahydro-6-[(4-hydroxyphenyl)Methyl]-8-(1-naphthalenylMethyl)-4,7-dioxo-N-(phenylMethyl)-2H-pyrazino[1,2-a]pyriMidine-1(6H)-carboxaMide
- (S,S)-ICG 001
- CAS:
- 780757-88-2
- MF:
- C33H32N4O4
- MW:
- 548.63
- Product Categories:
-
- Inhibitors
- Mol File:
- 780757-88-2.mol
ICG-001 Chemical Properties
- Melting point:
- 133-134℃
- Boiling point:
- 895.6±65.0 °C(Predicted)
- Density
- 1.37
- storage temp.
- Store at -20°C
- solubility
- DMSO:30.0(Max Conc. mg/mL);54.68(Max Conc. mM)
- form
- A crystalline solid
- pka
- 9.88±0.15(Predicted)
- color
- White to off-white
- InChIKey
- HQWTUOLCGKIECB-XZWHSSHBSA-N
- SMILES
- [C@]12([H])CN(CC3=C4C(C=CC=C4)=CC=C3)C(=O)[C@H](CC3=CC=C(O)C=C3)N1C(=O)CCN2C(NCC1=CC=CC=C1)=O
ICG-001 Usage And Synthesis
Uses
ICG 001 is a small molecule inhibitor of Wnt/β-catenin signaling.
Definition
ChEBI: (6S,9aS)-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-3,6,9,9a-tetrahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide is a peptide.
in vivo
ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling in mice, while concurrently preserving the epithelium[2]. Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent MK-231, which has consistently demonstrated efficacy in this model. ICG-001 (150 mg/kg, i.v.) demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss in the SW620 nude mouse xenograft model of tumor regression[3].
storage
-20°C
ICG-001Supplier
- Tel
- 020-13556033878 2965585218 13556033878
- chemcell@hotmail.com
- Tel
- sales@boylechem.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com